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Hepatic involvement in mitochondrial cytopathies rarely manifests in adulthood, but is a common fea-
ture in children. Multiple OXPHOS enzyme defects in children with liver involvement are often associated
with dramatically reduced amounts of mtDNA. We investigated two novel large scale deletions in two
infants with a multisystem disorder and prominent hepatopathy. Amount of mtDNA deletions and pro-
tein content were measured in different post-mortem tissues. The highest levels of deleted mtDNA were
in liver, kidney, pancreas of both patients. Moreover, mtDNA deletions were detected in cultured skin
ﬁbroblasts in both patients and in blood of one during life. Biochemical analysis showed impairment
of mainly complex I enzyme activity. Patients manifesting multisystem disorders in childhood may har-
bour rare mtDNA deletions in multiple tissues. For these patients, less invasive blood specimens or cul-
tured ﬁbroblasts can be used for molecular diagnosis. Our data further expand the array of deletions in
the mitochondrial genomes in association with liver failure. Thus analysis of mtDNA should be consid-
ered in the diagnosis of childhood-onset hepatopathies.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The oxidative phosphorylation (OXPHOS) deﬁciencies represent
one of the major causes of metabolic disorders with a prevalence
estimated at 1/8500 birth [1]. These disorders represent a hetero-
geneous group of genetic diseases, mainly affecting brain, heart
and muscle, and can be caused by genetic defects in mitochondrial
(mt) or nuclear (n) DNA. OXPHOS catalyzes the oxidation of fuel
molecules by oxygen and the concomitant energy transduction
into ATP via ﬁve complexes, embedded in the inner mitochondrial
membrane. The mitochondrial OXPHOS is made up of about 100
different proteins, 13 of which are encoded by mtDNA and the oth-
ers by nDNA [2].
The high dependence of hepatocytes upon ATP production for
the correct biosynthetic and detoxifying pathways explains in part
why liver involvement is also a common feature in childhood
OXPHOS-related diseases, particularly in the neonatal period,rozzo).
Y-NC-ND license.where it may present as neonatal acute liver failure, hepatic steato-
hepatitis or cirrhosis with chronic liver failure of insidious onset
[3]. It is becoming obvious that conditions with markedly reduced
levels of mtDNA (mtDNA depletion, MDS) frequently cause liver
failure in early childhood [4], and syndromes associated with
prominent hepatic disease and related to mtDNA deletions are rare
[5]. Importantly, liver complications are often a late feature of a
multi-system disorder, such as Leigh syndrome [6].
We herein report on the clinical, biochemical and molecular
features in two children in which a multisystem disorder, resem-
bling Pearson syndrome, was associated to a prominent hepatopa-
thy and related to novel mtDNA large-scale rearrangements
encompassing multiple genes of NADH-ubiquinone oxidoreductase
(complex I).2. Materials and methods
2.1. Case reports
Details of the clinical features of both patients are summarized in
Case reports of Supplementary methods. Both patients manifested
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ﬁrst 2 years of life associated with some features resembling Pear-
son syndrome such as pancytopenia with non-hemolitic megalob-
lastic anaemia, signs of pancreatic failure and severe lactic acidosis.
2.2. Tissues
Muscle and skin biopsieswere obtainedpre-mortem,whereas all
other tissues were sampled 1 h after death once obtained informed
parental consent. All tissues were immediately frozen in liquid
nitrogen and stored at 80 C until assayed. Autoptic tissues,
whereas available, were obtained from age-matched controls (kids
who died for nometabolic causes) and frozen following similar pro-
cedures than patients. Human ﬁbroblasts were grown in DMEM
medium supplemented with 10% foetal bovine serum, 4.5 g/L glu-
cose and 50 lg/mL uridine.
2.3. Histological and electron microscopy studies
Frozen sections of muscle biopsy were stained for haematoxylin
and eosin (HE), Gomori trichrome, cytochrome c oxidase, and suc-
cinate dehydrogenase [7]. The liver specimens were processed for
light and electron microscopy. Light microscopy studies included
routine stains, HE and Masson trichrome. Ultrathin sections were
analysed using a Zeiss 109 electron microscope [8].
2.4. Biochemical and molecular studies
Spectrophotometric determination of respiratory chain enzymes
activities in bioptic and autopticmuscle, and in autoptic liver tissue,
Southern blotting, SDS–PAGE/Western blotting, genomic DNA puri-
ﬁcation and PCR ampliﬁcation (in ﬁbroblasts and autoptic tissues)
used previously reportedmethodologies [9–11]. To deﬁne precisely
the breakpoints of the deletions, we used a ‘‘primer shifting’’ PCR-
based strategy as reported elsewhere [12], and mtDNA (GenBank
ID: NC_012920) oligonucleotide primer sets 16,470–8330, 6900–
16,470 and 7250–16,470 for patient 1, and sets 10,500–16,569 and
11,500–16,430 for patient 2. Finemapping of the deletionswas per-
formedbydirect sequencingusing the BigDyeTerminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA) on an
ABI3130xl automatic DNA Analyzer. Determination of the relative
abundance of wild-type and deleted genomes used either an ad
hoc designed ‘‘3-primer last hot-cycle’’ PCR method [13,14] or a
quantitative real-timePCR (qPCR) assay [15,16], or both (see Supple-
mentary methods). For SDS–PAGE, 50 lg of proteins from different
tissues were loaded in a 12% denaturating gel. Immunoreactivity
of the following proteins was ascertained using monoclonal anti-
bodies purchased from Mitosciences (Eugene, OR, USA): complex
I—15 kDa subunit (NDUFB4), 20 kDa subunit (NDUFB8), 30 kDa sub-
unit (NDUFS3), and 39 kDa subunit (NDUFA9); complex II—70 kDa
subunit (SDH70); complex III—core 2 subunit (core2); complex
IV—subunit II (CIV-II); and complex V—subunit alfa (CVa). Reactive
bands were detected using the ImmobilonWestern Chemilumines-
cent HRP Substrate Detection Kit (Millipore Corporation, Billerica,
MA, USA). Fluorescencewas quantiﬁed using the Quantity One Soft-
ware (BioRad, Hercules, CA, USA). Each sample was run in triplicate
and normalized valueswere averaged and compared to normal con-
trol tissues.3. Results
In patient 1, liver histology showed a micronodular cirrhosis
(Fig. 1A top) with ductular reaction and marked cholestasis. Hepa-
tocytes were ballooned, occasionally with multinuclei, microvesic-
ular steatosis and haemosiderosis (Fig. 1B top). At the electronmicroscopy (Fig. 1C top) the liver showed an accumulation of mito-
chondria, which also appeared round and with few and dysregu-
lated cristae. The liver histology in patient 2, showed preserved
architecture with mild portal ﬁbrosis (Fig. 1A bottom). Hepatocytes
had an oncocytic appearance due to an increased number of mito-
chondria, sometimes with megamitochondria (Fig. 1B bottom). In
addition, ballooning degeneration, micro and macrovesicular stea-
tosis, cholestasis, and ductular proliferation were present. At the
electron microscopy (Fig. 1C bottom) the liver showed an accumu-
lation of mitochondria even more pronounced than in patient 1; in
some mitochondria the cristae were almost absent. Moreover, an
accumulation of lipids drops were observed.
Spectrophotometric determination of the activities of respira-
tory chain complexes in patient 1 showed 73% reduction of complex
I in autopticmuscle homogenates (themuscle biopsy specimenwas
inconsistent for spectrophotometric studies), and multiple defects
in autoptic liver with undetectable activity of complex I, 12% of
residual activity of complex III and 39% residual activity of complex
IV, upon correction for the levels of citrate synthase. In patient 2, we
detected an isolated defect of complex I (residual activity 40%) in
bioptic and autoptic muscle, as well as in autoptic liver, with 17%
residual activities compared to the lowest range of controls. In
mitochondria isolated from cultured ﬁbroblasts complex I activity
was almost undetectable in patient 1, and 50% reduced in patient 2.
In ﬁbroblasts Southern blot analysis identiﬁed, in addition to the
wild type molecules, two smaller bands sized approximately
11.0 Kb in patient 1 (Fig. 2A) and 13.0 Kb in patient 2 (Fig. 2B).
The bands corresponded to heteroplasmic mtDNA deletions. There
was no evidence for reduced amount of mitochondrial genomes
(data not shown). Fine mapping of the deletions disclosed that
patient 1 harboured a 5312 base pairs (bp) long deletion, extending
from nucleotide nt. 10,090 in NADH-dehydrogenase, subunit 3
(ND3) to nt. 15,402 in cytochrome b (CYTB), and patient 2 a
2837-bp, from nt. 12,366 in NADH-dehydrogenase, subunit 5
(ND5) to nt. 15,203 in CYTB. The novel deletion identiﬁed in patient
1 removed ﬁve tRNAs (R-H-S2-L2- and E), large part of complex I ND
subunits (part of ND3, ND4L, ND4, ND5, and ND6), and a small re-
gion of cytochrome b; whereas, the new deletion in patient 2
removed the sequences of ND5, ND6, part of cytochrome b and
the tRNAGlu gene. The deletions were not ﬂanked by direct repeats.
Using radiolabelled 30-PCR, the very high levels of deleted
mtDNA was found in liver tissue of both patients (92% and 89%,
respectively in patients 1 and 2); whereas the other tissues showed
values ranging from 68% to 86% in patient 1, and from 33% to 94%
for patient 2 (Supplementary Fig. 1) with very high levels particu-
larly in kidney and pancreas. Similar data were observed using
qRT-PCR method (Supplementary Fig. 2). Values obtained from
both methods are compared in Table 1.
Western blot analysis showed a clear decreased amount of
NDUFB4 and NDUFB8 complex I nuclear encoded subunits in tis-
sues from patient 2 (Fig. 3A and B), while other nuclear encoded
subunits such as NDUFA9, NDUFS3 were normally present or only
mildly reduced. In detail, NDUFB4 and NDUFB8 subunits were not
detected in liver, markedly reduced in kidney and relatively re-
duced in skeletal muscle, but seemed to be preserved in heart.
Complex II, III, IV and V subunits were normally expressed
(Fig. 3C). No sufﬁcient material was available for patient 1.4. Discussion
Single deletions of mtDNA are usually associated with 3 major
clinical conditions: Kearns–Sayre syndrome (KSS) (MIM 530000),
Pearson syndrome (MIM 557000), and chronic progressive external
ophthalmoplegia (CPEO) (MIM 157640). Typically, single mtDNA
deletions are sporadic events occurring in isolated members of a
Fig. 1. Histological and electron microscopy in liver tissue of patient 1 (top) and patient 2 (bottom). (A) Masson trichrome, 4; (B) hematossilin eosin (HE), 40; (C) electron
microscopy (EM), 1500 magniﬁcation (Bars, 2500 nm). The Masson thrichrome showed in patient 1 (top-A) disturbed architecture due to ﬁbrotic septa around hepatic
nodules. The HE (top-B) evidences ballooned hepatocytes with multinuclei and microvesicular steatosis. Sometimes megamitochondria are present (arrow). With EM (top-C)
the mitochondria appeared round with a less electron-dense matrix and markedly reduced cristae. In patient 2 by Masson trichrome (bottom-A) the architecture is preserved;
only mild portal ﬁbrosis is evident. The HE (bottom-B) shows oncocytic hepatocytes rich in mitochondria (asterisks). The EM (bottom-C) displays a heavy accumulation of
mitochondria throughout the hepatocytes. Again, note the loss of cristae in these mitochondria. Lipids drops are present.
Fig. 2. Southern blotting of total ﬁbroblasts DNA from patient 1 (A) and patient 2
(B). DNA digestion of patient 1 was performed using PvuII (P) restriction enzyme;
for patient 2: PvuII (P), BamHI (B), and SnaBI (S) were used. Total humanmtDNA was
used as a probe. The bands at 16.6 kb represent the wild-type mtDNA while the
smaller ones represent partial deleted mtDNAs. P1 and P2: patient 1 and 2,
respectively. C1 and C2: controls 1 and 2, respectively.
Table 1
Relative percentage of mtDNA deleted molecules in post-mortem tissues and in blood
from patients 1 and 2 by using two different quantitative techniques.
Last cycle hot-PCR qRT-PCR
Patient 1
Fibroblasts 67.8 ± 3.1 54.6 ± 4.6
Liver 91.6 ± 9.6 89.3 ± 1.1
Spleen 86.2 ± 0.1 82.1 ± 6.3
Skeletal muscle 83.8 ± 2.7 80.8 ± 1.7
Pancreas 84.6 ± 3.1 82.1 ± 1.2
Kidney 83.2 ± 2.3 89.5 ± 0.4
Patient 2
Fibroblasts 33.6 ± 3.5 33.9 ± 10.7
Heart 66.8 ± 2.2 62.2 ± 3.8
Liver 88.7 ± 3.0 93.5 ± 0.7
Skeletal Muscle 79.2 ± 3.7 80.5 ± 1.4
Pancreas 83.5 ± 3.3 92.3 ± 0.4
Lung 86.6 ± 2.8 83.6 ± 0.9
Kidney 89.0 ± 2.6 94.2 ± 0.3
Blood 83.3 ± 0.1 n.d.
Adrenal Gland 89.8 ± 2.4 86.1 ± 5.4
n.d.: not-determined.
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germline [17].
The patients herein described both present with a multisystem
disorder mainly affecting the liver with signs of Pearson’s syn-
drome and associated to a single, large-scale mtDNA deletion.
The deletions found in our patients have never been described
before, and were ubiquitously distributed in all tissues. They re-
moved at least one tRNA and several subunits of complex I, which
is consistent with the profound biochemical defect identiﬁed in all
examined tissues. The expected profound defect in protein content
was demonstrated by Western blotting analyses with a prominentreduction of complex I subunits. Unexpectedly we found an un-
even reduction of some complex I nuclear encoded subunits in
some tissues compared to others. NDUFB4 and NDUFB8 subunits
were markedly reduced only in liver, kidney and skeletal muscle
while NDUFA9, NDUFS3 subunits appeared to be comparatively
normal or only mildly reduced. While it is complex to explain
the cause of uneven distribution of complex I subunits in different
Fig. 3. Western blotting in post-mortem tissues of patient 2. (A) Homogenates from post-mortem tissues were separated by SDS–PAGE, and antibodies against subunits of
complex I (NDUFA9, NDUFS3, NDUFB8, NDUFB4), and complex II (SDH 70 kDa) were used; (B) Histograms corresponding to the normalized expression protein. K, Lv, H, SM:
kidney, liver, heart and skeletal muscle from patient; LvC, HC, SMC: liver, heart and skeletal muscle from control; (C) SDS–PAGE of patient’s kidney and liver using antibodies
against complex II (SDH 70 kDa), complex V (alpha), complex III (core 2), and complex IV (COX II). Complex I subunits content was normalized to the mitochondrial protein
SDH70 used as a control for equal loading. All tissues were referred to its own control, except for kidney (control was not available) that was normalized to liver control,
considering the similar amount of protein subunits seen in (C). Low content of NDUFB8 and NDUFB4 subunits is evident in liver, kidney, and skeletal muscle, whereas
NDUFA9, NDUFS3 as well as complex II, III, and IV subunits are normally expressed.
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of complex I nuclear encoded NDUFB4 and NDUFB8 subunits com-
pared to others analysed, i.e. NDUFA9, NDUFS3. Complex I is the
largest and least understood component of the respiratory chain.
It consists of 45 different subunits that assemble together into a
structure of 1 MDa [18]. The assembly of subunits into complex
I has proved to be a very puzzling problem to address, complicated
by the size of the enzyme and its dual genomic control. Newly im-
ported subunits, encoded by the nuclear genome must assemble in
coordination with subunits encoded by mtDNA. Loss of many of
the mtDNA-encoded ND subunits and underexpression of some
of those coded by nDNA likely make the holocomplex less stabile
and partially assembled [19]. For instance, the ND1, ND4, and
ND6 subunits are essential for correct assembly of complex I, since
there is evidence that their mutations are associated with mark-
edly reduced levels of the enzyme [20–22]. Therefore, it is reason-
able to think that in our patients the lack of many ND subunits
make the holocomplex less stabile and partially assembled. More-
over, it has been seen that in the absence of mtDNA-encoded sub-
units, the levels of some nDNA-encoded subunits of the peripheral
arm remain unchanged [22] as conﬁrmed by our Western blotting
experiments. In fact, our results display a normal or mildly reduced
content of NDUFA9 and NDUFS3 subunits, which are both compo-
nents of the peripheral arm [23–26]. On the other hands, the pref-
erential loss in our experiments of the two smaller nuclear
encoded subunits NDUFB4 and NDUFB8 could be explained by
their position, being part of the subcomplex Ib, which is composed
mainly by the mtDNA subunits and form the hydrophobic mem-
brane arm of complex I [27].
In agreement with other studies, we observed a wide tissue dis-
tribution of deleted genomes [28] and it is likely that the functional
status of each tissue will ultimately depend upon the accumulation
of deleted mtDNA species [29]. Our results suggest a gross correla-
tion between the amount of mtDNA deletedmolecules and the con-
tent of related protein. In fact, liver, kidney and skeletal muscle
showed the highest level of deletion and the lower content of
NDUFB4 and NDUFB8 subunits. Whereas in heart, in which the
amount of deletion is below70%,we reveal a normal amountof com-
plex I subunits. These ﬁndings lead us to hypothesise a possible
threshold effectwhen themtDNAdeletedmolecules exceed the70%.
Hepatic involvement in primary (i.e. genetic) mitochondrial dis-
orders rarely manifests in adulthood, but is a common feature in
childhood respiratory chain disease, particularly in the neonatal
period [30,31]. In some infants, liver dysfunction may spontane-
ously reverse or remain stable, but in some there is rapid progres-
sion to cholestasis, coagulopathy, and ascites. Biochemical studies
reveal single or multiple respiratory chain enzymes defects, whichmay be restricted to the liver and remain undetectable in skeletal
muscle or skin ﬁbroblasts [6]. Prominent liver involvement is
rarely related to primary pathogenic point mutations [32], or single
deletions of mtDNA [33], but is most often associated with condi-
tions characterized by reduced amounts of mtDNA in affected tis-
sues and grouped as MDS [34–36].
It is well established that single mtDNA deletions are generally
associated to Pearson’s [37], KSS [38], CPEO syndromes [39] and that
surviving patients with Pearson can later present with a KSS [40].
More rarely other syndromes have been reported to be associated
to mtDNA rearrangements such as the Villous Atrophy syndrome
[41], and the ‘‘common’’ mtDNA deletion once associated to early
onset liver and renal failure [33]. Moreover, in addition to KSS and
CPEO syndromes, the mtDNA deletions have been detected also in
patients with chronic tubulointerstitial nephropathy [42,43].
When suspecting a mitochondrial disorder with prominent
hepatic involvement the biochemical defects may not always be
apparent in unaffected tissues, and a liver biopsy may be indicated
[6]. However, our experience shows that mtDNA deletions can be
easily detected in patients’ cultured ﬁbroblasts as well as in blood
cells. This conﬁrms previous experience [28] suggesting less inva-
sive techniques, particularly in neonates, such as cultured skin
ﬁbroblasts or blood sample that can be tested preliminarily for
mtDNA deletions before analysing nuclear genes related to mtDNA
depletion.
Regardless of the ultimate pathomechanisms, our data further
expand the array of deletions in the mitochondrial genomes and
its association with liver failure, and as such analysis of mtDNA
should be considered in the diagnostic algorithm of childhood-
onset hepatopathies.
Finally, we used two different methods to measure the amount
of mtDNA-deleted molecules, the radiolabelled 30-PCR and the
qRT-PCR. The results obtained allow us to suggest the use of the fas-
ter and safer qRT-PCR instead of the radiolabelled 30-PCR method.Acknowledgments
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